Vitality Watch

Dossier pubmed review 08-may-2026
Narrative review or expert overview without new data

Ergothioneine as a potential geroprotector: Targeting molecular hallmarks of ageing and age-related diseases.

Key claim: A systematic review argues that ergothioneine, selectively accumulated via OCTN1, targets multiple molecular hallmarks of ageing and is an emerging geroprotective candidate warranting rigorous clinical healthspan evaluation.

Abstract

Hypothesized to be a diet-derived ‘longevity vitamin’, Ergothioneine (ET) is increasingly recognized for its potential to modulate cellular homeostasis and support healthy ageing in preclinical models. This systematic review, encompassing evidence from 2005 to 2025, investigates ET’s unique pharmacokinetics mediated by the OCTN1 (SLC22A4) transporter, which ensures its selective accumulation in tissues susceptible to age-related oxidative decline. Beyond its role as a secondary antioxidant buffer, we critically evaluate ET’s ability to target molecular hallmarks of ageing, specifically focusing on telomere maintenance, mitochondrial integrity, and the NRF2-mediated cytoprotective response. Utilizing network pharmacology, this review deciphers the multi-target regulatory landscape of ET in mitigating neurodegeneration, cardiovascular remodeling, and metabolic dysfunction. Furthermore, we address clinical gaps by discussing ET’s potential utility as a candidate biomarker of biological aging and emphasizing the necessity of precision nutrition strategies incorporating SLC22A4/SLC22A15 genetic stratification. By synthesizing mechanistic insights and longitudinal human data, we highlight ET as an emerging candidate with geroprotective potential that warrants rigorous clinical evaluation for extending healthspan.

Why this matters

Ergothioneine is one of the few diet-derived small molecules with a plausible case as both a modifiable input and a biomarker of aging, because humans express a dedicated transporter (OCTN1) for it and blood levels decline with age. A systematic review consolidating mechanistic and longitudinal human data raises its profile as a candidate geroprotector, but no interventional trial has yet shown that raising ergothioneine moves any validated aging clock or hard outcome — the standard clock-movement-as-de-aging trap still applies.

Source

Link

Briefing card

Ergothioneine as a potential geroprotector: Targeting molecular hallmarks of ageing and age-related diseases.
Stage: review · pubmed · 08-may-2026

A systematic review argues that ergothioneine, selectively accumulated via OCTN1, targets multiple molecular hallmarks of ageing and is an emerging geroprotective candidate warranting rigorous clinical healthspan evaluation.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.arr.2026.103158

build build 880 · 2bcef25 · 2026-11-18